Oral Presentations

1400-1500 MONDAY AFTERNOON

EFFECT OF THE CYP3A5 6986A>G POLYMORPHISM ON TACROLIMUS PHARMACOKINETICS IN LIVER TRANSPLANT RECIPIENTS: A META-ANALYSIS
Buendia JA¹, Bramuglia G²,Staatz CE³. ¹Pharmacology and Toxicology Department. Faculty of Medicine. University of Antioquia, Colombia. Email: Jefferson.buendia@gmail.com. ²Faculty of Pharmacy and Biochemistry. University of Buenos Aires, Argentina. Email: gfbramuglia@gmail.com. ³School of Pharmacy, University of Queensland. Australia. Email:chris@pharmacy.uq.edu.au.

IMPACT OF CYP3A4*22 ALLELE ON TACROLIMUS PHARMACOKINETICS IN EARLY PERIOD AFTER RENAL TRANSPLANTATION: TOWARDS UPDATED GENOTYPE-BASED DOSING GUIDELINES.
Elens Laure^1,2, Capron Arnaud^1,3, van Schaik Ron HN², Wallemacq Pierre^1,3, Michel Mourad⁴, Vincent Haufroid^1,3. ¹Louvain centre for Toxicology and Applied Pharmacology (LTAP), Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain , Brussels, Belgium; ²Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands; ³Laboratory of Analytical Biochemistry, Cliniques universitaires St Luc, , Université catholique de Louvain, Brussels, Belgium; ⁴Surgery and Abdominal Transplantation Division, Cliniques universitaires St Luc, Université catholique de Louvain, Brussels, Belgium.

INFLUENCE OF CYP3A4, CYP3A5 AND MDR1-C3435T GENETIC POLYMORPHISMS IN TACROLIMUS PHARMACOKINETICS IN ADULT RENAL TRANSPLANT PATIENTS
Salvador-Garrido P, Outeda-Macías M, Seoane-Pillado MT, Pedreira-Vázquez I, Martín-Herranz I. Pharmacy Service. University Hospital of A Coruña. Xerencia de Xestión Integrada A Coruña. A Coruña. Spain.

INTERACTION BETWEEN TACROLIMUS AND NICARDIPINE IN A PEDIATRIC RENAL TRANSPLANT WITH CYTOCHROME P450 3A LOSS-OF-FUNCTION GENOTYPES
PROMIS AS¹, FROGER C¹, LAROCHE ML¹, SAINT-MARCOUX F¹, SALAS C², GUIGONIS V², WOILLARD JB¹, MARQUET P¹, PICARD N¹. ¹CHU Limoges, Department of Pharmacology, Toxicology and Pharmacovigilance, Limoges, France (the two first authors contributed equally to this work); ²CHU Limoges, Department of paediatrics, Mother & Child Hospital, Limoges, France.

EFFECT OF THE CYP3A5 GENOTYPE OF RECIPIENTS AND DONORS ON TACROLIMUS PHARMACOKINETICS IN LIVER TRANSPLANT RECIPIENTS.
Jefferson Antonio Buendía¹, Esteban Otamendi³, Fernando Cairo³, Andres Ruf³, Maria de Davila³, Paula Schaiquevich², Yanina Powazniak⁴, Julieta Nafissi⁴, Alberto Lazarowski², Guillermo Bramuglia^2,4 and Federico Villamil³. ¹Pharmacology and Toxicology Department. Faculty of Medicine. University of Antioquia, Colombia. ²Faculty of Pharmacy and Biochemistry. University of Buenos Aires, Argentina. ³CIPREC, Buenos Aires, Argentina. ⁴Fundacion Investigar, Buenos Aires. Argentina.

PREDICTION OF THE HEMATOCRIT OF DRIED BLOOD SPOTS VIA POTASSIUM MEASUREMENT ON A ROUTINE CLINICAL CHEMISTRY ANALYZER
Capiau S¹, Stove VV², Lambert WE¹, Stove CP¹. ¹Laboratory of Toxicology, Ghent University, Harelbekestraat 72, 9000 Ghent, Belgium; ²Department of Clinical Chemistry, Ghent University Hospital, Ghent, Belgium; E-mail:christophe.stove@ugent.be.

DEVELOPMENT AND CLINICAL EVALUATION OF A DRIED URINE SPOT METHOD FOR DETERMINATION OF HIPPURIC ACID AND CREATININE.
Antunes MV, Niederauer C, Linden R. Universidade Feevale, Novo Hamburgo – RS, Brazil.

DRIED BLOOD SPOTS AS AN ALTERNATIVE SAMPLING STRATEGY FOR CYP1A2 PHENOTYPING.
De Kesel PMM, Lambert WE, Stove CP. Laboratory of Toxicology, Faculty of Pharmaceutical Sciences, Ghent University, Harelbekestraat 72, 9000 Ghent, Belgium. Email:pieter.dekesel@ugent.be.

DETERMINATION OF VENLAFAXINE AND O-DESMETHYLVENLAFAXINE IN DRIED BLOOD SPOTS USING LC-MS/MS.
E.J.J. Berm¹, E. Brummel-Mulder², J. Paardekooper², E. Hak³, B. Wilffert¹, J.G. Maring². ¹Department of Pharmacy, section Pharmacotherapy and Pharmaceutical Care , University of Groningen, the Netherlands. ²Laboratory for Drug Analysis &Toxicology, Diaconessen Hospital Meppel& Bethesda Hospital Hoogeveen, the Netherlands. ³Deptartment of Pharmacy, section PharmacoEpidemiology and PharmacoEconomics, University of Groningen, the Netherlands.

ANALYSIS OF ATYPICAL ANTIPSYCHOTICS: COMPARISON OF DRIED BLOOD SPOT CARDS.
Fisher DS, Partridge SJ, Flanagan RJ. Toxicology Unit, King’s College Hospital, London, UK.

RESOLUTION OF INTERFERENCES IN DEVELOPMENT AND CLINICAL VALIDATION OF A TURBULENT-FLOW LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRIC METHOD FOR POSACONAZOLE AND VORICONAZOLE IN SERUM
Schofield.R¹, Breaud.A², Clarke.W², Bechtel.L³. ¹Chemistry Service, Department of Laboratory Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York. ²Department of Pathology, the Johns Hopkins Hospital, Baltimore, MD. ³Forensic Laboratories, Denver, CO.

MONITORING OF AMPHOTERICIN B IN HUMAN PLASMA AND CSF BY HPLC: A CASE REPORT.
Liu S，Dai Q. Department of Pharmacy, Southwest Hospital, Third Military Medical University, Chongqing，China.

A PRACTICAL THRICE WEEKLY ERTAPENEM DOSAGE REGIME FOR CHRONIC HEMODIALYSIS PATIENTS.
Bosma M¹,*,de Man P^1,2, Rietveld A^1,3, Touw D⁵, Geerlings C.^1,4. ¹Sint Franciscus Gasthuis, Rotterdam, The Netherlands. ²Department of microbiology. ³Department of Nephrology, ⁴Hospital Pharmacy. ⁵Hospital Pharmacy, Apotheek Haagse Ziekenhuizen, Den Haag, The Netherlands. *Presently no affiliation

THERAPEUTIC DRUG MONITORING GUIDED EXTENDED AMINOGLYCOSIDES DOSING REGIMEN IN PAEDIATRIC CYSTIC FIBROSIS (CF) PATIENTS: A STEP FOREWARD.
Tesfaye H¹, Jedlickova B¹, Prusa R¹, Bartosova J², Kucerova T², Skalicka V². Kreslova M³. ¹Department of Medical Chemistry and Clinical Biochemistry, Division of Clinical Pharmacology. ²Department of Paediatrics, Faculty Hospital in Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic. ³Department of Paediatrics, Faculty Hospital in Plzen, Czech Republic.

SIMULTANEOUS QUANTIFICATION OF 17 ANTIBIOTICS IN HUMAN PLASMA USING LC-MS/MS FOR ROUTINE BASIS TDM.
Woloch C, Dupuy C, Lefeuvre S, Poinsignon V, Gutmann L and Billaud EM. CHU Paris Ouest – HEGP, Paris Descartes University, Pharmacology, Microbiology, 75015 Paris, France.

1600-1700 MONDAY AFTERNOON

DETECTION OF 57 DRUGS AND METABOLITES IN MECONIUM BY LIQUID CHROMATOGRAPHY-TIME OF FLIGHT MASS SPECTROMETRY.
Rasmussen, N.N.¹, Marin, S.J.², Clark, C.J.¹, McMillin, G.A.^2,3. ¹ARUP Laboratories, Salt Lake City, UT. ²ARUP Institute for Experimental and Clinical Pathology, Salt Lake City, UT. ³University of Utah Department of Pathology, Salt Lake City, UT.

DEVELOPMENT OF A QUALITATIVE URINE DRUG PANEL BY LIQUID CHROMATOGRAPHY TIME OF FLIGHT MASS SPECTROMETRY (LC-TOF-MS)
Lawlor B.G.¹, Marin S.J.², Chittamma A.², Clark C.J.¹, McMillin G.A.^1,3. ¹ARUP Laboratories, Inc., Salt Lake City, UT; ²ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT; ³Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT.

DEVELOPMENT OF A HIGH RESOLUTION MASS SPECTROMETRY METHOD FOR URINE DRUG SCREENING.
Thoren KL, Lynch KL, Shugarts SB, Wu AHB. Department of Laboratory Medicine, University of California San Francisco and San Francisco General Hospital, CA 94110.

STUDIES ON THE METABOLISM AND THE DETECTABILITY OF CAMFETAMINE IN RAT URINE USING GC-MS AND LC-(HR)-MSⁿ TECHNIQUES.
Welter J¹, Kavanagh P², and Maurer HH¹. ¹Department of Experimental and Clinical Toxicology, Saarland University, Homburg (Saar), Germany. ²Department of Pharmacology and Therapeutics, St. James’s Hospital, Dublin, Ireland.

DETECTION OF in utero MARIJUANA EXPOSURE BY THREE METHODS USING UMBILICAL CORD TISSUE.
Williams J.A.¹, Marin S.J.², Chittamma A.¹, Clark, C.¹, McMillin G.A.^1,3. ¹ARUP Laboratories, Inc., Salt Lake City, UT. ²ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT. ³Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT.

RELATIONSHIP BETWEEN DRUG-DRUG INTERACTIONS, MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2 (MRP2) FUNCTION AND METHOTREXATE CLEARANCE IN ADULTS WITH LYMPHOID MALIGNANCIES.
Benz-de Bretagne I.¹, Le Gouge A.², Zahr N.³, Hulot J.S.³, Leblond V.⁴, Hoang-Xuan K.⁵, Gyan E.⁶, Lissandre S.⁶, Choquet S.⁴, Le Guellec C.¹. ¹Laboratory of Biochemistry and Molecular Biology, CHU of Tours, François Rabelais University, PRES Centre Val de Loire Université, EA4245, Tours, France; ²Clinical Investigation Center, Inserm 202, Tours, France ; ³Pharmacology Department, Pitié-Salpêtrière Hospital, Paris, France ; ⁴Hematology Department, Pitié-Salpêtrière Hospital, Paris, France ; ⁴Neurology Department, Pitié-Salpêtrière Hospital, Paris, France ; ⁶Hematology and Cellular Therapy, CHU of Tours, Tours, France.

CLINICAL PHARMACOKINETICS OF DORIPENEM AND MEROPENEM IN PROSTATE TISSUE, AND DOSING CONSIDERATIONS FOR PROSTATITIS BASED ON SITE-SPECIFIC PHARMACODYNAMIC TARGET ATTAINMENT.
Ikawa K¹, Nakamura K², Nishikawa G², Yamada Y³, Zennami K², Mitsui K⁴, Narushima M⁵, Ikeda K¹, Morikawa N¹, Sumitomo M². ¹Department of Clinical Pharmacotherapy, Hiroshima University, Hiroshima; ²Department of Urology, Aichi Medical University School of Medicine, Aichi; ³Department of Urology, Gifu Social Insurance Hospital, Gifu; ⁴Department of Urology, Tokoname Municipal Hospital, Aichi; ⁵Department of Urology, Meitetsu Hospital, Aichi, Japan.

AN EXTERNAL EVALUATION OF VANCOMYCIN PHARMACOKINETICS AMONG SEPTIC NEONATES.
Bhongsatiern, J.^1,2, Sherwin, C.M.T.¹, Stockmann, C.¹ Yu, T.¹, Reith, D.M.³, Desai, P.B.², Spigarelli, M.G.¹. ¹Department of Pediatrics, Div. of Clinical Pharmacology, University of Utah. ²James L. Winkle College of Pharmacy, University of Cincinnati. ³Dept. of Women’s and Children’s Health, University of Otago, Dunedin, New Zealand.

THE NEXT GENERATION PHARMACOKINETIC SOFTWARE SUITE, Edsim++ AND MwPharm++, PROVIDE CLINICIANS THE MEANS TO DEVELOP AND USE PK/PD MODELS IN A CLINICAL SETTING.
Potůček J., Douša J., Punt N¹. Mediware a.s. Evropská 655/116, 160 00 Praha 6, Czech republic. ¹Medimatics, Praaglaan 131, 6229 HR, Maastricht, The Netherlands.

MODELING OF THE EXPOSURE TO TACROLIMUS IN KIDNEY TRANSPLANTATION.
Ben Fredj N.¹, Woillard J.B.², Debord J.², Chaabane A.¹, Chadly Z.¹, Ben Fadhel N.¹, Boughattas N.¹, Marquet P.², Saint-marcoux F.², Aouam K¹. ¹Department of Pharmacology, Monastir, Tunisia. ²Department of Pharmacology, Limoges University Hospital, France.

PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MONITORING OF MYCOPHENOLATE MOFETIL IN de novo AND LONG-TERM RENAL TRANSPLANT PATIENTS.
Molinaro M¹, Chiarelli L.R², Segoloni G.P³, Libetta C⁴, Dal Canton A⁴, Regazzi M¹. ¹Clinical and Experimental Pharmacokinetics Unit, Fondazione IRCCS Policlinico S.Matteo – Pavia; ²Department of Biology and Biotechnology, University of Pavia; ³Division of Nephrology, Dialysis and Transplantation, San Giovanni Battista Hospital – Torino; ⁴Unit of Nephrology, Dialysis and Transplantation, Fondazione IRCCS Policlinico S.Matteo – Pavia, (Italy).

DYNAMIC CHARACTERISTICS OF IMMUNE REGULATORY STATE IN ALLO-LIVER RECIPIENTS WITH TACROLIMUS-BASED REGIMEN.
Bei Cai¹, Yi Li¹, Yangjuan Bai¹, Yuangao Zou¹, Lvnan Yan², Lanlan Wang¹*. ¹Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China. ²Center of Liver Transplantation, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China. *Corresponding author, e-mail: wanglanlan999@163.com.

SIROLIMUS AND EVEROLIMUS IMMUNOASSAY CROSS-REACTIVITY IN A PATIENT WITH TUBEROUS SCLEROSIS.
Kieffer TW, Zimmerman MK. Indiana University School of Medicine, Indianapolis, IN.

EVEROLIMUS QMS ASSAY BY USING THERMOFISHER INDIKO, BECKMAN DXc AND AU680 ANALYZERS AND LIMITED COMPARISON TO LC-MS/MS.
K. Garrison¹, K. L.Johnson-Davis², S.H. Wong³. ¹Wake Forest Baptist Health, Winston-Salem, NC. ²ARUP and University of Utah, Salt Lake City, UT. ³Wake Forest School of Medicine, Winston-Salem, NC.

SYSTEMATIC CONVERSION TO GENERIC TACROLIMUS IN STABLE KIDNEY TRANSPLANT PATIENTS.
Rosenborg S^1,2, Nordström A¹, Almquist T³, Wennberg L⁴, Bárány P². Clinics of ¹Clinical Pharmacology, ²Nephrology and ³Transplantation Surgery, Karolinska University Hospital, and ⁴Nephrology at Danderyd’s Hospital, Stockholm, Sweden.

1400-1500 WEDNESDAY AFTERNOON

CD26 EXPRESSION ON T-CELLS AND DIPETIDYL PEPTIDASE IV (DPPIV) ACTIVITY IN PLASMA AS A COMPLEMENTARY TOOL TO THERAPEUTIC DRUG MONITORING (TDM) IN STABLE KIDNEY TRANSPLANT (KTx) PATIENTS.
Shipkova M, Strobel S, Leicht S, Bolley R, Wilhlem J, Wollmeyer J, Klett, C, Olbricht C, Wieland E. Klinikum Stuttgart, Stuttgart. Germany.

NFAT-REGULATED CYTOKINE EXPRESSION DURING TACROLIMUS THERAPY EARLY AFTER TRANSPLANTATION.
Bremer S¹, Johansson ED^1,2, Pham L^1,2 Vethe NT³ Line P-D⁴ Midtvedt K⁵ Skauby M⁴ Hole K^2,3, Berg C^2,3, Bergan S^2,3. ¹Department of Medical Biochemistry, Oslo University Hospital, Norway. ²School of Pharmacy, University of Oslo, Norway. ³Dept. of Pharmacology, Oslo University Hospital, Norway. ⁴Department of Transplantation, Oslo University Hospital, Norway. ⁵Department of Transplant Medicine, Oslo University Hospital, Norway.

IFN-&#947, IL-17 AND IL-2 AS PREDICTIVE BIOMARKERS OF ACUTE REJECTION IN LIVER AND KIDNEY TRANSPLANTATION: RESULTS OF A MULTICENTER STUDY.
O. Millán^1,2, L. Rafael-Valdivia³, D. San Segundo⁴, F. Boix⁵, MJ. Castro-Panete⁶, M. López-Hoyos⁴, M. Muro⁵, D. Valero-Hervás⁶, A. Rimola^2,3, M. Navasab³, MA. De Cos⁷, M. Miras⁸, A. Andrés⁹, L. Guirado¹⁰, J. Pascual¹¹, M. Bruneta*. ¹Farmacología y Toxicología, Centro de Diagnóstico Biomédico, IDIBAPS, Hospital Clínico, Universidad de Barcelona, Barcelona, Spain. ²Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain. ³Unidad de Hígado, Hospital Clínico, IDIBAPS, Barcelona, Spain. ⁴Servicio de Inmunología, Hospital Universitario Marqués de Valdecilla-IFIMAV, Santander, Spain. ⁵Servicio de Inmunología, Hospital Universitario Virgen Arrixaca, Murcia, Spain. ⁶Servicio de Inmunología, Hospital Universitario 12 de Octubre, Universidad Complutense, Madrid, Spain. ⁷Farmacología Clínica, Hospital Universitario Marqués de Valdecilla-IFIMAV, Santander, Spain. ⁸Servicio de Medicina Digestiva Hospital Universitario Virgen Arrixaca, Murcia, Spain. ⁹Servicio de Nefrología, Hospital Universitario 12 de Octubre. Universidad Complutense. Madrid, Spain. ¹⁰Unidad de Trasplante Renal, Servico de Nefrologia, Fundació Puigvert, Barcelona, Spain. ¹¹Servicio de Nefrología, Hospital del Mar, Barcelona, Spain.

IMPDH ACTIVITY IN ex vivo-STIMULATED LYMPHOCYTES AS A MARKER OF MYCOPHENOLIC ACID RESPONSE IN RENAL TRANSPLANT RECIPIENTS.
Vethe NT¹, Hole K^1,2, Berg C^2,3, Bremer S³, Line P-D⁴ Midtvedt K⁵ Skauby M⁴, Andersen AM¹, Dahl Johansson E^2,3, Pham L^2,3, Bergan S^1,2. ¹Department of Pharmacology, Oslo University Hospital, Norway. ²School of Pharmacy, University of Oslo, Norway. ³Department of Medical Biochemistry, Oslo University Hospital, Norway. ⁴Department of Transplantation, Oslo University Hospital, Norway. ⁵Department of Transplant Medicine, Oslo University Hospital, Norway.

EX-VIVO PHARMACODYNAMICS OF TACROLIMUS ON THE LYMPHOCYTE CALCINEURIN PATHWAY: THE INTEGRATION OF SIGNALS.
Noceti O^1,2,3, Taupin J-L⁴, Boumediene A⁵, Esperón P³, Gerona S², Touriño C⁶, Marquet P¹. ¹INSERM UMR-S850, Laboratory of Medical Pharmacology, France; University of Limoges, France; CHU Limoges, France. ²Centro Nacional Hepato- Biliopancreático, National Transplant Liver Center, Hospital Central de las Fuerzas Armadas, Montevideo, Uruguay. ³Molecular Biology Unit, Clinical Biochemistry Department, School of Chemistry, Universidad de la Republica, Montevideo, Uruguay. ⁴CNRS-UMR 5164, Victor Segalen University, Bordeaux, France. ⁵Laboratory of Immunology, University Hospital Center Dupuytren, Limoges, France. ⁶Department of Fundamental Medicine, School of Medicine, Universidad de la Republica, Montevideo, Uruguay.

ASSESSMENT OF PASSIVE AND SYSTEMIC EXPOSURE TO DRUGS OF ABUSE IN CHILDREN THROUGH HAIR ANALYSIS.
Gareri J^1,2, Natekar A¹, Walasek P¹, Karaskov T¹, Koren G^1,2,3. ¹Motherisk Laboratory, Hospital for Sick Children, Toronto, Canada; ²Department of Pharmaceutical Science, University of Toronto, Toronto, Canada; ³Ivey Chair in Molecular Toxicology, University of Western Ontario, London, Canada.

NORCOCAINE AS A BIOMARKER IN HUMAN HAIR TO DIFFERENTIATE COCAINE USE FROM EXTERNAL EXPOSURE IN A HIGH-RISK POPULATION.
Poon, S^1,2, Walasek, P¹, Koren, G^1,2. ¹The Motherisk Program, Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, Canada; ²Department of Pharmacology &Toxicology, University of Toronto, Toronto, Canada.

POLYDRUG USE AMONG PREGNANT METHADONE USERS.
Delano, K., Gareri, J. and Koren, G. University of Toronto, Toronto, ON Canada; Department of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, ON Canada.>/span>

ASSESSMENT OF ARSENIC TOXICITY USING A COMBINATION OF QUANTITATIVE SCREENING AND CHROMATOGRAPHIC SEPARATION WITH INDUCTIVELY COUPLED PLASMA-MASS SPECTROMETRY.
Wise P.¹, Haglock C.J.², Strathmann F.G.^2,3. ¹ARUP Laboratories, Salt Lake City, UT; ²ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT; ³University of Utah, Department of Pathology, Salt Lake City, UT.

A TOXICOKINETIC-TOXICODYNAMIC MODEL FOR PARAQUAT IN HUMANS.
Flora T. Musuamba¹, Klintean Wunnapuk^2,3, Fahim Mohammed^4,5,6, Indika Gawarammana^4,5,6, Rorger K. Verbeeck^1,7, Nicholas A. Buckley^6,8,9, Michael S. Roberts^2,10, Pierre Wallemacq¹. ¹Louvain Drug Research Institute, Louvain Centre for Toxicology and Applied Pharmacology, Catholic University of Louvain, Brussels, Belgium. ²Therapeutics Research Centre, School of Medicine, University of Queensland, Brisbane, QLD, Australia. ³Department of Forensic Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. ⁴Department of Pharmacology, Faculty of Medicine, University of Ruhuna, Sri Lanka. ⁵Department of Medicine, Faculty of Medicine, University of Peradeniya, Sri Lanka. ⁶South Asian Clinical Toxicology Research Collaboration, Faculty of Medicine, University of Peradeniya, Sri Lanka. ⁷Faculty of Pharmacy, Rhodes University, Grahamstown, South Africa. ⁸Australian National University, Canberra, Australia. ⁹Professorial Medicine Unit, University of New South Wales, NSW, Australia. ¹⁰School of Pharmacy & Medical Science, University of South Australia, Adelaide, SA, Australia.

THE EFFECT OF GENETIC VARIATIONS IN CYTOCHROMES P450 3A, THE P450 OXYDOREDUCTASE (POR) AND THE NUCLEAR RECEPTOR PPARA ON SIROLIMUS in vitro METABOLISM, TROUGH LEVELS AND ADVERSE EVENTS IN KIDNEY TRANSPLANT RECIPIENTS.
Woillard JB^1,2,3, Kamar N^4,5,6, Coste S², Rostaing L^4,5,6, Marquet P^1,2,3, Picard N^1,2,3. ¹INSERM, UMR S-850, Limoges, France; ²Univ Limoges, Limoges, France; ³CHU Limoges, Department of Pharmacology and Toxicology, Limoges, France; ⁴CHU Toulouse, Department of Nephrology-Dialysis and Multi-Organ Transplantation, Toulouse, France; ⁵INSERM, U563, IFR–BMT, CHU Purpan, Toulouse, France; ⁶Univ Paul Sabatier, Toulouse, France.

EVALUATING THE EFFECT OF CYP3A4 AND CYP3A5 POLYMORPHISMS ON CYCLOSPORINE, EVEROLIMUS AND TACROLIMUS PHARMACOKINETICS IN RENAL TRANSPLANTATION PATIENTS.
Moes D.J.A.R^1,2, Swen J.J.¹, den Hartigh J¹, van der Straaten T.¹, Homan van der Heide J.J. Bemelman F., de Fijter J.W.² , Guchelaar H.J.¹. ¹Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands. ²Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands. ³Department of Nephrology, Academical Medical Center, Amsterdam, The Netherlands. ⁴Department of Nephrology, University Medical Centre Groningen, Groningen, The Netherlands.

THE IMPACT OF CYP3A5*3 POLYMORPHISM ON SIROLIMUS PHARMACOKINETICS: NOVEL INSIGHTS FROM A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING APPROACH
Emoto C¹, Fukuda T^1,2, Venkatasubramanian R^1,3, Cox S¹, Christians U⁴, and Vinks A. A.^1,2. ¹Division of Clinical Pharmacology, Cincinnati Children’s Hospital Medical Center. ²Department of Pediatrics, University of Cincinnati College of Medicine. ³Department of Anesthesia, Cincinnati Children’s Hospital Medical Center. ⁴iC42 Integrated Solutions in Clinical Research and Development, University of Colorado.

ASSOCIATION BETWEEN INTRA-RENAL P-gp EXPRESSION AND CYCLOSPORINE CONCENTRATIONS IN RENAL TRANSPLANTATION.
Sallustio B^1,2, Noll B¹, Coller J², Somogyi A². Department of Clinical Pharmacology, The Queen Elizabeth Hospital¹, South Australia; Discipline of Pharmacology, University of Adelaide², South Australia.

GENETIC VARIATIONS IN MEMBRANE TRANSPORTERS AND THE DECREASE IN NEUTROPHILS INDUCED BY GANCICLOVIR THERAPY: AN EXPLORATORY STUDY IN RENAL TRANSPLANT PATIENTS.
BILLAT P-A.¹, SAINT-MARCOUX F.^1,2, WOILLARD J-B.^1,2 MERVILLE P.³, ROSTAING L.⁴, KAMAR N.⁴, REROLLE J-P.⁵, ESSIG M.^1,5, MARQUET P.^1,2, PICARD N.^1,2. ¹Inserm UMR S-850, Laboratoire de Pharmacologie médicale, Faculté de médecine, Limoges – FRANCE. ²Service de Pharmacologie, Toxicologie et Pharmacovigilance, CHU Limoges, Limoges – FRANCE. ³ Hôpital Pellegrin, CHU Bordeaux, Service de Néphrologie, Transplantation, Dialyse, Bordeaux – FRANCE. ⁴CHU Toulouse Rangueil, Service de Néphrologie, HTA, Dialyse et Transplantation d’Organes, Toulouse – FRANCE. ⁵Service de Néphrologie, CHU Limoges, Limoges – FRANCE.

A POTENTIAL FOR INDIVIDUALIZED DOSING OF PREDNISOLONE IN PEDIATRIC RENAL TRANSPLANT RECIPIENTS.
Skauby RH, Bjerre AK, Sæves I, Bergan S. Dept of Medical Biochemistry, Dept of Pharmacology, Dept of Pediatrics, Oslo University Hospital, Norway.

MULTIPLE MODEL OPTIMAL (MMOPT) SAMPLING FOR FIRST DOSE ORAL VORICONAZOLE TDM IN CHILDREN
Neely MN¹, Bayard DS¹, Hope WW². ¹Laboratory of Applied Pharmacokinetics, Children’s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, USA. ²Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.

FREQUENCY OF ACHIEVING THE THERAPEUTIC RANGE WITH VANCOMYCIN IN INFANTS, CHILDREN AND ADOLESCENTS.
Constance, J.E., Balch, A., Campbell, S.C., Stockmann, C., Sherwin, C.M.T., Spigarelli, M.G. Dept. of Pediatrics, Div. of Clinical Pharmacology, University of Utah.

ESTIMATING FAT-FREE MASS IN CHILDREN.
Al-Sallami HS¹, Goulding A², Williams S², Grant A², Taylor R², Duffull SB¹. ¹School of Pharmacy, University of Otago, Dunedin – New Zealand. ²School of Medicine, University of Otago, Dunedin – New Zealand.

PEDIATRIC UNDERREPRESENTATION IN THERAPEUTIC DRUG MONITORING STUDIES.
Stockmann, C., Sherwin, C.M.T., Constance, J.E., Campbell, S.C, Linakis, M., Yu, T., Balch, A., Spigarelli, M.G. Dept. of Pediatrics, Div. of Clinical Pharmacology, University of Utah.

1600-1700 WEDNESDAY AFTERNOON

HIGH-THROUGHPUT VALIDATED METHOD FOR THE QUANTIFICATION OF LACOSAMIDE IN SERUM USING ULTRA FAST SPE-MS/MS.
Korman E.; Bjergum M.; Danso D.; Erbsen J.; Enger R.; Langman L. Ph.D; Jannetto P. Ph.D . Mayo Clinic Rochester, MN 55905 USA.

A UPLC-MS/MS METHOD FOR THERAPEUTIC DRUG MONITORING OF ETONOGESTREL
Tiffany Thomas¹, Kelsey Petrie², Joonho Shim³, Kirsten M Abildskov¹, Carolyn L Westhoff², Serge Cremers¹. ¹Irving Institute for Clinical and Translational Research, Columbia University Medical Center, New York, NY, USA. ²Obstetrics and Gynecology, Columbia University Medical Center, New York, NY, USA. ³INHA University School of Medicine, Incheon, South Korea.

DEVELOPMENT OF A MASS SPECTROMETRIC IMMUNOASSAY FOR DIGOXIN.
Wilson R¹, Couchman L¹, Krastins B², Flanagan RJ¹. ¹King’s College Hospital, London, SE5 9RS, UK. ²ThermoFisher Scientific BRIMS Center, Cambridge, MA, USA.

DETERMINATION OF RIVAROXABAN IN HUMAN PLASMA BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY –TANDEM MASS SPECTROMETRY AND CORRELATION WITH CHROMOGENIC ASSAY.
Tamigniau A¹, Capron A¹, Douxfils J², Dogné JM², Chatelain B³, Wallemacq P¹. ¹Laboratory of Clinical Chemistry, Saint-Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium/²Departement of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Université de Namur, Namur, Belgium/³Hematology Laboratory, NTHC, NARILIS, CHU Mont-Godinne, Université Catholique de Louvain, Mont-Godinne, Belgium.

THERAPEUTIC DRUG MONITORING OF LEVETIRACETAM IN CLINICAL PRACTICE.
Salvador-Garrido P, Outeda-Macías M, Martínez-López LM, Martín-Herranz I.
Pharmacy Service. University Hospital of A Coruña. Xerencia de Xestión Integrada A Coruña. A Coruña. Spain.

POPULATION PHARMACOKINETIC MODELING OF SUNITINIB WITH THE ABCG2 GENOTYPE IN PATIENTS WITH RENAL CELL CARCINOMA.
Mizuno T.^1,2, Fukuda T.^1,6, Terada T.⁴, Fukudo M.², Dong M.¹, Kamba T.³, Yamasaki T.³, Ogawa O.³, Katsura T.², Inui K.⁵, Vinks A.A.^1,6. ¹Division of Clinical Pharmacology, Cincinnati Children’s Hospital Medical Center, Cincinnati, USA. ²Department of Pharmacy, Kyoto University Hospital, Kyoto Japan. ³Department of Urology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. ⁴Department of Pharmacy, Shiga University of Medical Science Hospital, Otsu, Japan. ⁵Kyoto Pharmaceutical University, Kyoto, Japan. ⁶Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, USA.

POPULATION PHARMACOKINETIC ANALYSIS OF DOCETAXEL AND SORAFENIB AND CHARACTERIZATION OF THEIR DRUG-DRUG INTERACTIONS WHEN CO-ADMINISTERED IN CHEMO-NAÏVE PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER.
Flora T Musuamba^1,2, Feby Mardjuadi³, Jean Pascal Machiels³, Pierre Wallemacq² and Roger K Verbeeck¹. ¹Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium. ²Louvain Centre for Toxicology and Applied Pharmacology, Université catholique de Louvain, Brussels, Belgium. ³Service d’oncologie médicale, Cliniques universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC, MIRO), Université catholique de Louvain, Brussels, Belgium.

GENOTYPE BASED DOSING MAY IMPROVE OUTCOMES AFTER BUSULFAN CONDITIONING.
Bremer S¹, Fløisand Y² and Bergan S³. ¹Dept. of Medical Biochemistry, Oslo University Hospital, Norway. ²Dept. of Hematology, Oslo University Hospital, Norway. ³Dept. of Pharmacology, Oslo University Hospital, Norway.

UNRELIABILITY OF FIXED BUSULFAN DOSING SCHEDULE AND THE VITAL ROLE OF THERAPEUTIC DRUG MONITORING IN PAEDIATRIC HAEMOPOIETIC STEM CELL TRANSPLANTATION (HSCT) CONDITIONING THERAPY.
¹Tesfaye H, ¹Branova R, ¹Klapkova E, ¹Prusa R., ²Janeckova D, ²Sedlacek P, ²Riha P, ²Keslová P, ²Krol L., ²Malis J., ²Sumerauer D., ²Sevec M.². ¹Department of Medical Chemistry and Clinical Biochemistry, Division of Clinical Pharmacology, ²Department of Paediatric Haematology and Oncology, Faculty Hospital in Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.

HIGH- THROUGHPUT VALIDATED METHOD FOR THE QUANTITAION OF BUSULFAN IN PLASMA USING ULTRA-FAST SPE-MS/MS.
Darlington Danso; Matthew Bjergum; Robert Enger; Paul Jannetto Ph.D; Loralie Langman Ph.D. Mayo Clinic, Rochester, MN, Rochester, MN.

CYCLOSPORINE IN HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS: COMBINATION OF PHARMACOKINETIC TOOLS TO INCREASE THE RELIABILITY OF DOSE ADJUSTMENT.

Woillard JB^1,2, Lebreton V¹, Neely M³, Turlure P⁴, Giraut S⁴, Debord J^1,2, Marquet P^1,2, Saint-Marcoux F^1,2. ¹Pharmacology Department, CHU Limoges, France. ²INSERM UMR-S850, Univ Limoges, France. ³Laboratory of Applied Pharmacokinetics, University of Southern California Keck School of Medicine, Los Angeles, CA, USA. ⁴Department of Hematology, CHU de Limoges, France.

NONPARAMETRIC APPROACH FOR POPULATION PHARMACOKINETIC STUDY OF TACROLIMUS IN HEART TRANSPLANT PATIENTS.
Youdarene R¹, Woillard JB^1,2, Fruit D^1,2, Marquet P^1,2, Saint-Marcoux F^1,2. ¹Service de Pharmacologie, Toxicologie et Pharmacovigilance, CHU Limoges, France. ²INSERM UMR-S850, Univ Limoges, France.

A NON-PARAMETRIC APPROACH TO DEVELOP A BAYESIAN ESTIMATOR FOR TACROLIMUS IN RENAL TRANSPLANT PATIENTS.
Ben Fredj N.¹, Woillard J.B.², Debord J.¹, Chaabane A.¹, Chadly Z.¹, Ben Fadhel N.¹, Boughattas N.¹, Marquet P.², Saint-marcoux F.², Aouam K¹.¹Department of Pharmacology, Monastir, Tunisia. ²Department of Pharmacology, Limoges University Hospital, France.

INDIVIDUAL DOSAGE OF DIGOXIN WITH CALCULATED AND MEASURED CONCENTRATION IN CONTEMPORARY MEDICINE.
Zhao Li, Zhang Di, Zhang Xianglin. Department of pharmacy, China-Japan friendship hospital, Beijing, 100029, China.

MONITORING OF PLASMA RIBAVIRIN – DATA FROM A TDM LABORATORY 2011 TO PRESENT.
Morgan PE¹, Brown NW², Barnabas A¹, Agarwal K¹, Tredger JM^1,3. ¹Institute of Liver Studies, King’s College Hospital, London SE5 9RS, UK. ²Department of Clinical Chemistry, Wansbeck General Hospital, Ashington NE63 9JJ, UK. ³
King’s College London.

SIROLIMUS AND FK506 DIFFERENTLY MODULATE THE EXPRESSION OF PD-1 AND HVEM ON CD4+ REGULATORY T CELLS IN ALLO-RENAL RECIPIENTS.
Yangjuan Bai¹, Yi Li¹, Yunying Shi², Yang Fu¹, Bei Cai¹, Yuangao Zou¹, Lanlan Wang*¹. ¹Division of Clinical Immunology, Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, P.R.China. ²Department of Nephrology, West China Hospital, Sichuan University, Chengdu, Sichuan, P.R.China. *Corresponding author.

INTEGRATED TARGETED QUANTITATION METHOD FOR INSULIN AND ITS THERAPEUTIC ANALOGS.
Eric Niederkofler¹, Dobrin Nedelkov¹, Urban Kiernan¹, David Phillips¹, Kemmons Tubbss¹, Scott Peterman², Bryan Krastins², Amol Prakash², Mary Lopez². ¹Thermo Fisher Scientific, Tempe, AZ. ²Thermo Fisher Scientific BRIMS, Cambridge, MA.

THERAPEUTIC MONITORING OF VANCOMYCIN IN NEONATES: IS THERE A COST TO NON-ADHERENCE OF GUIDELINES?
Firth, S.D.¹, Yakub, S.Y.¹, Sherwin, C.M.T.¹, Korgenski, E.K.², Constance, J.E.¹, Balch, A.¹, Spigarelli, M.G.¹. ¹Dept. of Pediatrics, Div. of Clinical Pharmacology, University of Utah. ²Intermountain Healthcare, Pediatric Clinical Program, University of Utah.

SEQUENTIAL PHARMACOKINETIC GANCYCLOVIR EXPOSURE AFTER LOW DOSE VALGANCYCLOVIR PROPHYLAXIS IN KIDNEY TRANSPLANT RECIPIENTS – AN INTERIM ANALYSIS.
Mathew BS¹, Basu G, Abraham AM², Vijayakumar TS, Ratna Prabha¹, Fleming DH¹. ¹Clinical Pharmacology Unit, Department of Nephrology, ²Department of Clinical Virology, Christian Medical College, Vellore, Tamil Nadu, India.

1430-1530 THURSDAY AFTERNOON

DIRECT ANALYSIS OF 26 URINARY OPIOIDS AND METABOLITES BY MIXED-MODE µELUTION SPE COMBINED WITH UPLC/MS/MS – IMPROVED PERFORMANCE VS. “DILUTE-AND-SHOOT” METHODOLOGY.
Danaceau, J., Chambers, E., Fountain, K. Waters Corporation.

HIGH-THROUGHPUT AND SELECTIVE FORENSIC DRUG SCREENING IN URINE USING A SPE/MS/MS SYSTEM
Romm M, Schlicht K, Parikh N, Youssef M, Miller V, and LaMarr W. Agilent Technologies Inc., Wakefield, MA.

ONE FOR ALL, ALL IN ONE: DETERMINATION OF GAMMA-HYDROXYBUTYRIC ACID IN BIOFLUIDS USING “IN-VIAL” DERIVATIZATION AND HEADSPACE-TRAP GAS CHROMATOGRAPHY-MASS SPECTROMETRY.
Ingels AS^1,3, Neels H², Lambert WE¹, Stove CP¹. ¹Laboratory of Toxicology, Ghent University, Harelbekestraat 72, 9000 Ghent, Belgium; ²Laboratory of Toxicology, Antwerp University, Drie Eiken Campus, 2000 Antwerp, Belgium; ³Current address: Federal Public Service Justice, National Institute of Criminalistics and Criminology, Vilvoordsesteenweg 100, 1120 Brussels, Belgium. E-mail: christophe.stove@ugent.be.

DETERMINATION OF THE TRICYCLIC ANTIDEPRESSANTS AMITRIPTYLINE, NORTRIPTYLINE, IMIPRAMINE, DESIPRAMINE, CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE IN DRIED BLOOD SPOTS USING LC-MS/MS.
E.J.J. Berm¹, J. Paardekooper², E. Brummel-Mulder², E.Hak³, B. Wilffert¹, J.G. Maring². ¹Dept. of Pharmacy, section Pharmacotherapy and Pharmaceutical Care , University of Groningen, the Netherlands. ²Laboratory for Drug Analysis &Toxicology, Diaconessen Hospital Meppel& Bethesda Hospital Hoogeveen,the Netherlands. ³Dept. of Pharmacy, section PharmacoEpidemiology and PharmacoEconomics, University of Groningen, the Netherlands.

THE EFFECTS OF UNBOUND MYCOPHENOLIC ACID (MPA) ON INOSINE MONOPHOSPHATE DEHYDROGENASE (IMPDH) INHIBITION IN PEDIATRIC KIDNEY TRANSPLANT PATIENTS.
Smits T, BS¹, Cox S, BS¹, Fukuda T, PhD^1,2, Vinks A, PharmD, PhD^1,2. ¹ Division of Clinical Pharmacology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA.
²Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.

DEVELOPMENT OF A LC-MS/MS METHOD TO DETERMINE MYCOPHENOLIC ACID CONCENTRATION IN HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS.
Minh Thuan Nguyen Thi, Arnaud Capron, Pierre Wallemacq. Université catholique de Louvain, Louvain center for Toxicology and Applied Pharmacology (LTAP), Brussels.

ABBREVIATED MPA-AUC IN LUNG TRANSPLANTATION IN COMPARISON WITH THE IMMUNE CELL RESPONSE.
Schütz E¹, Warnecke G², Fegbeutel C², Haverich A², Oellerich M³. ¹Center of Molecular Diagnostics of IVM, University Goettingen, Goettingen, Germany. ²Department of Cardiothoracic, Transplantation and Vascular Surgery (HTTG), Hannover Medical School, Hannover, Germany. ³Department of Clinical Chemistry, University Medical Center Goettingen, Goettingen, Germany.

IMPACT OF RECIPIENT AND DONOR MULTIDRUG RESISTANCE PROTEIN 2 GENETIC VARIABILITY ON MYCOPHENOLIC ACID PHARMACOKINETICS FOLLOWING KIDNEY TRANSPLANTATION.
Md Dom ZI^1,2, Coller JK², Somogyi AA², Sallustio BC^1,2. ¹Department of Clinical Pharmacology, Queen Elizabeth Hospital, Woodville, SA; ²Discipline of Pharmacology, School of Medical Sciences, Faculty of Health Sciences, University of Adelaide, Adelaide, SA, Australia.

PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF MYCOPHENOLIC ACID: IMPROVED PREDICTION OF ABSORPTION AND ENTEROHEPATIC RECYCLING.
Ralf Stemkens, BSc^1,2, Min Dong, PhD¹, Raja Venkatasubramanian, PhD^1,3, Viera Lukacova, PhD⁴, Grazyna Fraczkiewicz, MSc⁴, Tsuyoshi Fukuda, PhD^1,5, Alexander A. Vinks, PharmD, PhD^1,5. ¹Division of Clinical Pharmacology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA. ²Faculty of Pharmacy, University of Utrecht, Utrecht, Netherlands. ³Department of Anesthesia, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA. ⁴Simulations Plus, Inc., Lancaster, CA, USA. ⁵Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.

MC4R rs489693: A CLINICAL RISK FACTOR FOR SECOND GENERATION ANTIPSYCHOTIC-RELATED WEIGHT GAIN.
Czerwensky F¹, Leucht S², Steimer W¹. ¹Institut für Klinische Chemie und Pathobiochemie and ²Klinik für Psychiatrie und Psychotherapie. Klinikum rechts der Isar der Technischen Universität München, Ismaninger Str. 22 81675 München.

TRANSPORTER GENETIC POLYMORPHISMS ASSOCIATED WITH VARIABLE MORPHINE PHARMACOKINETICS IN CHILDREN.
Fukuda T^1,3, Mizuno T¹, Chidambaran V^2,3, Venkatasubramanian R^1,2, Ngamprasertwong P^2,3, Niu J^1,2, Esslinger H¹, Vinks A^1,3, Sadhasivam S^2,3. ¹Division of Clinical Pharmacology, ²Department of Anesthesia, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA. ³University of Cincinnati College of Medicine, Cincinnati, OH.

IMPACT OF CYP2C19 POLYMORPHISMS ON PHARMACOKINETICS AND PHARMACODYNAMICS OF LOW-DOSE CLOBAZAM THERAPY IN JAPANESE PATIENTS WITH EPILEPSY.
Sachiyo Hashi¹, Mai Shibata², Satohiro Masuda¹, Kazuo Matsubara¹, Masako Kinoshita³, Riki Matsumoto⁴, Akio Ikeda⁴, Ryosuke Takahashi⁴, Ikuko Yano^1,2. ¹Department of Pharmacy, Kyoto University Hospital, Kyoto, Japan. ²Department of Clinical Pharmacy and Education, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan. ³Department of Neurology, Utano National Hospital, National Hospital Organization, Kyoto, Japan. ⁴Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

IMPACT OF POR*28 ON THE CLINICAL PHARMACOKINETICS OF CYP3A PHENOTYPING PROBES MIDAZOLAM AND ERYTHROMYCIN.
Laure Elens^1,2, Annemieke J.M. Nieuweboer³, Stephen J. Clarke⁴, Kellie A. Charles⁵, Anne-Joy M. de Graan³, Vincent Haufroid², Teun van Gelder^6,7, Ron H.J. Mathijssen³, Ron H.N. van Schaik¹. ¹Depts of Clinical Chemistry, ³Medical Oncology, ⁶Internal Medicine and ⁷Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands, ²Louvain centre for Toxicology and Applied Pharmacology (LTAP), Université catholique de Louvain, Brussels, Belgium, ⁴Dicipline of Medicine, Sydney Medical School-Northern, University of Sydney, NSW, Australia and ⁵Discipline of Pharmacology, School of Medical Sciences and Bosch Institute, University of Sydney, NSW, Australia.

DIMETHOCAINE, A SYNTHETIC COCAINE DERIVATIVE: STUDIES ON ITS IN VIVO AND IN VITRO METABOLISM AND ITS DETECTABILITY IN URINE.
Meyer MR, Lindauer C, Welter J, and Maurer HH. Department of Experimental and Clinical Toxicology, Saarland University, Homburg (Saar).

11-Nor-9-CARBOXY-∆9-TETRAHYDROCANNABINOL QUANTIFICATION IN HUMAN ORAL FLUID BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY
Scheidweiler KB¹, Himes SK¹, Chen X², Liu HF², and Huestis MA¹. ¹ Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA. ²ABSciex 353 Hatch Drive, Foster City, CA 94404, USA.

DEVELOPMENT OF A NOVEL TURBULENT FLOW CHROMATOGRAPHY MODE TO BE USED FOR FULLY AUTOMATED METABOLITE-BASED URINE SCREENING APPROACH USING AN LC-Q-EXACTIVE EQUIPMENT
Helfer AG, Meyer MR, Michely JA, Maurer HH. Department of Experimental and Clinical Toxicology, Saarland University, Homburg (Saar), Germany.

ADAPTATION OF URINE AND ORAL FLUID CEDIA IMMUNOASSAY TESTS FOR THE ANALYSIS OF RECREATIONAL DRUGS IN SERUM ON THE THERMO SCIENTIFIC INDIKO PLUS.
De Sloovere M.M.W., Stove V., Hollebosch M., Van Caeneghem E.,Verstraete A.G. Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium.

In Vitro CYTOCHROME P450 INHIBITION COCKTAIL ASSAY – PART II: DEVELOPMENT OF AN ALL-IN-ONE COCKTAIL APPROACH: DREAM OR REALITY?
Dinger J, Meyer MR, and Maurer HH. Department of Experimental and Clinical Toxicology, Saarland University, Homburg (Saar), Germany.